1. Blood Eosinophil Count and Outcomes in Severe Uncontrolled Asthma: A Prospective Study 
Robert S. Zeiger, MD, PhD, Michael Schatz, MD, MS, Anand A. Dalal, MBA, PhD, Wansu Chen, MS, PhD, Ekaterina Sadikova, MPH, Robert. Y. Suruki, ScD, Aniket A. Kawatkar, PhD, Lei Qian, PhD 
The Journal of Allergy and Clinical Immunology: In Practice 
Volume 5, Issue 1, Pages e8 (January 2017)
DOI: /j.jaip
Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Figure 1
The consort diagram and study design. Consort diagram depicts the administrative logistics used to identify the SUA cohort in phase I and the patients with SUA who participated in phase II with a blood eosinophil determination among the 207,814 KPSC members with a diagnosis of asthma in HEDIS, Healthcare Effectiveness Data and Information Set; ICD-9, International Classification of Diseases, Ninth Revision. *Comorbidities are listed in the Appendix, available in this article's Online Repository at
The Journal of Allergy and Clinical Immunology: In Practice 2017 5, e8DOI: ( /j.jaip )
Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3. Figure 2
Adjusted rate ratio and risk ratio (95% CI) for asthma exacerbations for each covariate in the regression models in severe uncontrolled asthma (SUA) for the blood eosinophil cutoff point of ≥400 cells/mm3 versus <400 cells/mm3 (panel A: asthma exacerbation rate; panel B: ≥1 asthma exacerbation; panel C: ≥2 asthma exacerbations; panel D: ≥1 asthma emergency department [ED] visit or hospitalization). Poisson regression models with robust error variance were used to estimate the adjusted rate and risk ratios and their 95% CIs.
The Journal of Allergy and Clinical Immunology: In Practice 2017 5, e8DOI: ( /j.jaip )
Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions